Recent progress in pharmaceutical therapies for castration-resistant prostate cancer
about
CYP17 inhibitors in prostate cancer: latest evidence and clinical potentialTherapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate CancerRecent advances in bone-targeted therapies of metastatic prostate cancerCYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents.Current treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasisCYP17A1 inhibitors in castration-resistant prostate cancerThe hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.Cancer survivors' perspectives and experience on western medicine and traditional Chinese medicine treatment and rehabilitation: a qualitative study.Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes.Extracting the Benefit of Nexrutine® for Cancer Prevention.Probing the prostate tumour microenvironment II: Impact of hypoxia on a cell model of prostate cancer progression.Targeting kallikrein-related peptidases in prostate cancer.Emerging agents for the therapy of advanced prostate cancer.Phase I and II therapies targeting the androgen receptor for the treatment of castration resistant prostate cancer.Cyclodextrin mediated delivery of NF-κB and SRF siRNA reduces the invasion potential of prostate cancer cells in vitro.A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with 223Radium-dichloride.
P2860
Q26740070-15758F98-A871-458B-B948-A4C925E2A0ECQ26750620-9E0A1714-793E-4AA0-AC05-1C35577267A5Q33703763-CF3D133E-555F-4F4A-8662-1FF49629BE71Q34387852-B7BB1536-3F31-4EDA-89BE-2F20712C2661Q34448130-C9A10915-7BA1-4002-BA75-6AB591F917E4Q34456638-88FAE63A-BFA2-4CC1-8DB7-C91425C9A5C8Q34525556-12F4669A-1C21-4366-874E-6352C65100B8Q34758040-35FAE0C8-47A2-4931-B7F7-A19B5C1AAAA6Q35013272-E9CBFD60-5571-4CED-ADA2-7F6D9371C3D7Q36236997-E175832F-45C8-4A46-A506-47D2AFF13140Q37716544-935E4345-580D-4AD4-85D4-2B668902B016Q38191293-7C00BB0E-A5B0-4B20-BA2C-76CAC140973BQ38586459-1719FDCB-0009-47FD-821B-5F565817E932Q38765489-C44CBDBC-0E40-4C2A-B43A-2E318C173AAFQ38871314-5D290DE1-E9DA-4841-B844-1D59074F2313Q47236071-684B4CDF-C0E5-4080-A359-898F700FE778
P2860
Recent progress in pharmaceutical therapies for castration-resistant prostate cancer
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Recent progress in pharmaceutical therapies for castration-resistant prostate cancer
@ast
Recent progress in pharmaceutical therapies for castration-resistant prostate cancer
@en
Recent progress in pharmaceutical therapies for castration-resistant prostate cancer
@nl
type
label
Recent progress in pharmaceutical therapies for castration-resistant prostate cancer
@ast
Recent progress in pharmaceutical therapies for castration-resistant prostate cancer
@en
Recent progress in pharmaceutical therapies for castration-resistant prostate cancer
@nl
prefLabel
Recent progress in pharmaceutical therapies for castration-resistant prostate cancer
@ast
Recent progress in pharmaceutical therapies for castration-resistant prostate cancer
@en
Recent progress in pharmaceutical therapies for castration-resistant prostate cancer
@nl
P2860
P356
P1476
Recent progress in pharmaceutical therapies for castration-resistant prostate cancer
@en
P2093
Rolf W Hartmann
P2860
P304
13958-13978
P356
10.3390/IJMS140713958
P407
P5008
P577
2013-07-04T00:00:00Z